March 24 (Reuters) - Immunitybio Inc IBRX.O:
IMMUNITYBIO- ACKNOWLEDGES RECEIPT OF OPDP LETTER DATED MARCH 13, REGARDING SOME PROMOTIONAL MATERIALS FOR ANKTIVAÒ (NOGAPENDEKIN ALFA INBAKICEPT-PMLN)
IMMUNITYBIO- TAKE FDA’S CONCERNS SERIOUSLY AND HAVE INITIATED A REVIEW OF LETTER WITH LEGAL AND REGULATORY TEAMS
IMMUNITYBIO: INTEND TO RESPOND TO FDA WITHIN REQUESTED TIMEFRAME AND WORK COOPERATIVELY WITH AGENCY TO ADDRESS MATTERS RAISED IN LETTER